Literature DB >> 28808892

Incidence Rates and Predictors of Colectomy for Ulcerative Colitis in the Era of Biologics: Results from a Provincial Database.

Maria Abou Khalil1,2, Marylise Boutros2,3, Hacene Nedjar4, Nancy Morin2,3, Gabriela Ghitulescu2,3, Carol-Ann Vasilevsky2,3, Philip Gordon2,3, Elham Rahme5,6,7.   

Abstract

BACKGROUND: We evaluated long-term incidence and identified risk factors of colectomy in pre-biologics and biologics eras for treatment of ulcerative colitis.
METHODS: After IRB approval, using data obtained from the Régie d'assurance maladie du Québec, we defined two cohorts: pre-biologics (1998-2004) and biologics (2005-2011) eras. Patients with inflammatory bowel disease or colectomy 1 year prior to first diagnosis of ulcerative colitis were excluded. Multivariate logistic regression model compared patient baseline characteristics. Kaplan-Meier curves displayed unadjusted time to event. Cox proportional hazards models were used to compare adjusted colectomy and mortality rates, respectively.
RESULTS: In pre-biologics and biologics eras, 335/2829 and 314/3313 patients, respectively, underwent colectomy. Median follow-up (first and third quartiles) was similar (p = 0.206). Incidence rates for colectomy were 36.08/1000 and 29.99/1000 patient years. Unadjusted rate of colectomy was higher in pre-biologics era (p = 0.004). Predictors of colectomy included anemia (1.66; 1.38-2.01), gastrointestinal hospitalizations (1.24; 1.04-1.47), congestive heart failure (2.08; 1.27-3.40), and male gender (1.47; 1.26-1.72). Mortality was 8.06 and 3.18% in pre-biologics and biologics eras. After adjusting for potential confounders, age (1.08; 1.05-1.12) and urgent colectomy (5.65; 2.19-14.54) remained associated with increased mortality hazard.
CONCLUSION: Incidence of colectomy decreased after introduction of biologics. Risk factors for colectomy were gastrointestinal hospitalizations, anemia, male gender, and congestive heart failure. Emergent surgery and age were predictors of mortality.

Entities:  

Keywords:  Biologics; Colectomy; Incidence; Predictors; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28808892     DOI: 10.1007/s11605-017-3530-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

Review 1.  Laparoscopic surgery for ulcerative colitis: a review of the literature.

Authors:  Keisuke Hata; Shinsuke Kazama; Hiroaki Nozawa; Kazushige Kawai; Tomomichi Kiyomatsu; Junichiro Tanaka; Toshiaki Tanaka; Takeshi Nishikawa; Hironori Yamaguchi; Soichiro Ishihara; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-10-28       Impact factor: 2.549

2.  Laparoscopic approach for inflammatory bowel disease is a real alternative to open surgery: an experience with 574 consecutive patients.

Authors:  Léon Maggiori; Antoine Khayat; Xavier Treton; Yoram Bouhnik; Eric Vicaut; Yves Panis
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

3.  Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.

Authors:  Christine Rungoe; Ebbe Langholz; Mikael Andersson; Saima Basit; Nete M Nielsen; Jan Wohlfahrt; Tine Jess
Journal:  Gut       Date:  2013-09-20       Impact factor: 23.059

4.  Course of ulcerative colitis: analysis of changes in disease activity over years.

Authors:  E Langholz; P Munkholm; M Davidsen; V Binder
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

5.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

6.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

7.  Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.

Authors:  Ryan Nelson; Chuanhong Liao; Alessandro Fichera; David T Rubin; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

8.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

9.  Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.

Authors:  Marianne K Vester-Andersen; Michelle V Prosberg; Tine Jess; Mikael Andersson; Bo G Bengtsson; Thomas Blixt; Pia Munkholm; Flemming Bendtsen; Ida Vind
Journal:  Am J Gastroenterol       Date:  2014-03-18       Impact factor: 10.864

10.  Female infertility after ileal pouch-anal anastomosis for ulcerative colitis.

Authors:  Paul Johnson; Carole Richard; Anat Ravid; Leia Spencer; Eleanor Pinto; Mary Hanna; Zane Cohen; Robin McLeod
Journal:  Dis Colon Rectum       Date:  2004-05-28       Impact factor: 4.585

View more
  13 in total

1.  Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades.

Authors:  Alexander Ni; Mohammed Al-Qahtani; Ebram Salama; Daniel Marinescu; Maria Abou Khalil; Julio Faria; Nancy Morin; Gabriela Ghitulescu; Carol-Ann Vasilevsky; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2020-06-15       Impact factor: 3.452

2.  Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.

Authors:  Maria Abou Khalil; Jad Abou-Khalil; Jennifer Motter; Carol-Ann Vasilevsky; Nancy Morin; Gabriela Ghitulescu; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

Review 3.  The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care.

Authors:  Jonathan A Beard; Diana L Franco; Benjamin H Click
Journal:  Curr Gastroenterol Rep       Date:  2020-01-30

4.  Elective surgery outcomes in inflammatory bowel disease: interpretation at magnetic resonance enterography.

Authors:  Giuseppe Cicero; Giorgio Ascenti; Alfredo Blandino; Renato Trimarchi; Christian Booz; Thomas J Vogl; Tommaso D'Angelo; Silvio Mazziotti
Journal:  Jpn J Radiol       Date:  2021-02-24       Impact factor: 2.374

5.  High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial.

Authors:  Mitsuro Chiba; Tsuyotoshi Tsuji; Kunio Nakane; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Yu Obara; Masafumi Komatsu; Haruhiko Tozawa
Journal:  Perm J       Date:  2020-11

6.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Authors:  M Ellen Kuenzig; Eric I Benchimol; Lawrence Lee; Laura E Targownik; Harminder Singh; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Sanjay K Murthy
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

Review 7.  Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment.

Authors:  Shintaro Akiyama; Victoria Rai; David T Rubin
Journal:  Intest Res       Date:  2020-11-05

8.  α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.

Authors:  Michaela Melde; Tanja M Müller; Ines Schneider; Carol-Immanuel Geppert; Laura Mühl; Laura Besendorf; Clarissa Allner; Emily Becker; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler
Journal:  Therap Adv Gastroenterol       Date:  2021-11-24       Impact factor: 4.409

Review 9.  Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis.

Authors:  Florian Kuehn; Richard A Hodin
Journal:  Visc Med       Date:  2018-10-31

10.  Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample.

Authors:  Babatunde Olaiya; Benjamin D Renelus; Mikolaj Filon; Sumona Saha
Journal:  Dig Dis Sci       Date:  2020-07-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.